Wakwaya Y, Ramdurai D, Swigris JJ. Managing cough in idiopathic pulmonary fibrosis. Chest. 2021;160(5):1774–82.

Article  PubMed  Google Scholar 

Singla A, Reuter S, Taube C, Peters M, Peters K. The molecular mechanisms of remodeling in asthma, COPD and IPF with a special emphasis on the complex role of Wnt5A. Inflamm Res. 2023;72(3):577–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, et al. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019;54(3):1900161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kropski JA, Blackwell TS. Progress in understanding and treating idiopathic pulmonary fibrosis. Annu Rev Med. 2019;70:211–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin C, Borensztajn K, Spek CA. Targeting coagulation factor receptors - protease-activated receptors in idiopathic pulmonary fibrosis. J Thromb Haemost. 2017;15(4):597–607.

Article  CAS  PubMed  Google Scholar 

Moss BJ, Ryter SW, Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis. Annu Rev Pathol. 2022;17:515–46.

Article  PubMed  Google Scholar 

Kadota T, Fujita Y, Araya J, Watanabe N, Fujimoto S, Kawamoto H, et al. Human bronchial epithelial cell-derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGF-β-WNT crosstalk. J Extracell Vesicles. 2021;10(10): e12124.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Della Latta V, Cecchettini A, Del Ry S, Morales MA. Bleomycin in the setting of lung fibrosis induction: from biological mechanisms to counteractions. Pharmacol Res. 2015;97:122–30.

Article  CAS  PubMed  Google Scholar 

Kolb P, Upagupta C, Vierhout M, Ayaub E, Bellaye PS, Gauldie J, et al. The importance of interventional timing in the bleomycin model of pulmonary fibrosis. Eur Respir J. 2020;55(6):1901105.

Article  CAS  PubMed  Google Scholar 

Pei Z, Qin Y, Fu X, Yang F, Huo F, Liang X, et al. Inhibition of ferroptosis and iron accumulation alleviates pulmonary fibrosis in a bleomycin model. Redox Biol. 2022;57: 102509.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22(7):381–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng L, He S, Guo N, Tian W, Zhang W, Luo L. Molecular mechanisms of ferroptosis and relevance to inflammation. Inflamm Res. 2023;72(2):281–99.

Article  CAS  PubMed  Google Scholar 

Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22(4):266–82.

Article  PubMed  PubMed Central  Google Scholar 

Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021. https://doi.org/10.1084/jem.20210518.

Article  PubMed  PubMed Central  Google Scholar 

Li M, Wang K, Zhang Y, Fan M, Li A, Zhou J, et al. Ferroptosis-related genes in bronchoalveolar lavage fluid serves as prognostic biomarkers for idiopathic pulmonary fibrosis. Front Med (Lausanne). 2021;8: 693959.

Article  PubMed  Google Scholar 

He Y, Shang Y, Li Y, Wang M, Yu D, Yang Y, et al. An 8-ferroptosis-related genes signature from bronchoalveolar lavage fluid for prognosis in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2022;22(1):15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma Z, Sun Y, Peng W. Fraxetin down-regulates polo-like kinase 4 (PLK4) to inhibit proliferation, migration and invasion of prostate cancer cells through the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) pathway. Bioengineered. 2022;13(4):9345–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee M, Yang C, Park S, Song G, Lim W. Fraxetin induces cell death in colon cancer cells via mitochondria dysfunction and enhances therapeutic effects in 5-fluorouracil resistant cells. J Cell Biochem. 2022;123(2):469–80.

Article  CAS  PubMed  Google Scholar 

Wu B, Wang R, Li S, Wang Y, Song F, Gu Y, et al. Antifibrotic effects of Fraxetin on carbon tetrachloride-induced liver fibrosis by targeting NF-κB/IκBα, MAPKs and Bcl-2/Bax pathways. Pharmacol Rep. 2019;71(3):409–16.

Article  CAS  PubMed  Google Scholar 

Hsieh Y-H, Hung T-W, Chen Y-S, Huang Y-N, Chiou H-L, Lee C-C, et al. In vitro and in vivo antifibrotic effects of fraxetin on renal interstitial fibrosis via the ERK signaling pathway. Toxins (Basel). 2021;13(7):474.

Article  CAS  PubMed  Google Scholar 

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jennings GC. Patient-doctor communication. N Z Med J. 1970;72(460):205.

CAS  PubMed  Google Scholar 

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fuhrmann DC, Mondorf A, Beifuß J, Jung M, Brüne B. Hypoxia inhibits ferritinophagy, increases mitochondrial ferritin, and protects from ferroptosis. Redox Biol. 2020;36: 101670.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu F, Zhang Q, Liu H, Liu J, Yang S, Luo X, et al. Dynamic O-GlcNAcylation coordinates ferritinophagy and mitophagy to activate ferroptosis. Cell Discov. 2022;8(1):40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shenderov K, Collins SL, Powell JD, Horton MR. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J Clin Invest. 2021. https://doi.org/10.1172/JCI143226.

Article  PubMed  PubMed Central  Google Scholar 

O’Dwyer DN, Ashley SL, Gurczynski SJ, Xia M, Wilke C, Falkowski NR, et al. Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med. 2019;199(9):1127–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Confalonieri P, Volpe MC, Jacob J, Maiocchi S, Salton F, Ruaro B, et al. Regeneration or repair? The role of alveolar epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Cells. 2022;11(13):2095.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79–91.

Article  CAS  PubMed  Google Scholar 

Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11(2):88.

Article  PubMed  PubMed Central  Google Scholar 

Battaglia AM, Chirillo R, Aversa I, Sacco A, Costanzo F, Biamonte F. Ferroptosis and cancer: mitochondria meet the “Iron Maiden” cell death. Cells. 2020;9(6):1505.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zheng D, Liu J, Piao H, Zhu Z, Wei R, Liu K. ROS-triggered endothelial cell death mechanisms: focus on pyroptosis, parthanatos, and ferroptosis. Front Immunol. 2022;13:1039241.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X, et al. Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials. 2021;277: 121110.

Article  CAS  PubMed  Google Scholar 

Wang X, Wang Y, Huang D, Shi S, Pei C, Wu Y, et al. Astragaloside IV regulates the ferroptosis signaling pathway via the Nrf2/SLC7A11/GPX4 axis to inhibit PM2.5-mediated lung injury in mice. Int Immunopharmacol. 2022;112